This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Huntington's Disease Rilmenidine study

  • Research type

    Research Study

  • Full title

    Huntington's Disease Rilmenindine Safety Trial

  • IRAS ID

    26759

  • Contact name

    Roger Barker

  • Sponsor organisation

    Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge

  • Eudract number

    2009-018119-14

  • ISRCTN Number

    n.a

  • Clinicaltrials.gov Identifier

    n.a

  • Research summary

    The proposed clinical drug trial is an open label safety study investigating a drug that has an action of autophagy in Huntington's Disease (HD). The medication being trialled is a drug that has been extensively used in humans previously for the treatment of hypertension. It has never been used before in HD however this drug has been shown to slow the disease down in animal models of HD. Given this and its good side effect profile and tolerability in people, it is a logical agent to try as a treatment in this currently incurable neurological condition.

  • REC name

    East of England - Cambridge South Research Ethics Committee

  • REC reference

    10/H0305/32

  • Date of REC Opinion

    23 Jul 2010

  • REC opinion

    Further Information Favourable Opinion